Lisata Therapeutics (LSTA) Asset Writedowns and Impairment (2016 - 2018)
Lisata Therapeutics filings provide 4 years of Asset Writedowns and Impairment readings, the most recent being -$1.4 million for Q2 2018.
- For the quarter ending Q2 2018, Asset Writedowns and Impairment fell 1173.03% year-over-year to -$1.4 million, compared with a TTM value of -$1.3 million through Jun 2018, down 200.9%, and an annual FY2025 reading of $100000.0, changed N/A over the prior year.
- Asset Writedowns and Impairment hit -$1.4 million in Q2 2018 for Lisata Therapeutics, down from $128492.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $62.3 million in Q4 2015, with the low at -$1.4 million in Q2 2018.
- Median Asset Writedowns and Impairment over the past 4 years was $128492.0 (2017), compared with a mean of $10.1 million.
- The sharpest move saw Asset Writedowns and Impairment plummeted 92.0% in 2017, then plummeted 1173.03% in 2018.
- Year by year, Asset Writedowns and Impairment stood at $62.3 million in 2015, then crashed by 100.95% to -$591307.0 in 2016, then skyrocketed by 121.73% to $128492.0 in 2017, then crashed by 1173.03% to -$1.4 million in 2018.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods came in at -$1.4 million, $128492.0, and $47301.0 for Q2 2018, Q2 2017, and Q1 2017 respectively.